Overview

AVE7688 in Patients With Mild to Moderate Blood Pressure

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the antihypertensive efficacy of 4 different AVE 7688 doses on the change from baseline in trough diastolic blood pressure at the end of week 12. The secondary objectives are: - To assess the antihypertensive efficacy of 4 different AVE 7688 doses on the change from baseline in trough systolic blood pressure at the end of week 12 - To compare the percentages of responders after 12 week of treatment - To evaluate the long term safety and tolerability of AVE 7688 with particular attention to angioedema
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Losartan